U
KERX

UBS’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

UBS’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$43K Sell
3,100
-31,400
-91% -$481K ﹤0.01% 7037
2014
Q2 		$531K Sell
34,500
-103,100
-75% -$1.46M ﹤0.01% 4171
2014
Q1 		$2.35M Buy
137,600
+126,600
+1,151% +$1.91M ﹤0.01% 2620
2013
Q4 		$142K Sell
11,000
-600
-5% -$7.17K ﹤0.01% 5674
2013
Q3 		$117K Sell
11,600
-9,100
-44% -$81K ﹤0.01% 5835
2013
Q2 		$155K Buy
+20,700
New +$162K ﹤0.01% 5384

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

UBS's KERX Position: Q3 2014 in Review

UBS increased its Keryx Biopharmaceuticals Inc (KERX) stake by 24% in Q3 2014, buying an estimated $439K and bringing the position to 150,630 shares worth $2.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2886.

UBS first reported a position in KERX in Q2 2013 and has held it in 6 quarters since. The position peaked at $3.01M in Q1 2014. 140 funds tracked by Wall St. Rank hold KERX as of Q3 2014.

  • UBS held 150,630 shares of Keryx Biopharmaceuticals Inc worth $2.07M as of Q3 2014.
  • UBS bought 28,692 Keryx Biopharmaceuticals Inc shares in Q3 2014, an estimated $439K.
  • Keryx Biopharmaceuticals Inc made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2886 holding.
  • UBS first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and has held it in 6 quarters since.
  • UBS's Keryx Biopharmaceuticals Inc position peaked at $3.01M in Q1 2014.
  • 140 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.